Syros Pharmaceuticals (SYRS) Tops Q3 EPS by 3c; Reports Cash and Cash Equivalents of $166.7M

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($0.41), $0.03 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $5.7 million versus the consensus estimate of $4.49 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance